Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope

Abstract Antibodies have been widely used for cancer therapy owing to their ability to distinguish cancer cells by recognizing cancer-specific antigens. Epidermal growth factor receptor (EGFR) is a promising target for the cancer therapeutics, against which several antibody clones have been develope...

Full description

Bibliographic Details
Main Authors: Koki Makabe, Takeshi Yokoyama, Shiro Uehara, Tomomi Uchikubo-Kamo, Mikako Shirouzu, Kouki Kimura, Kouhei Tsumoto, Ryutaro Asano, Yoshikazu Tanaka, Izumi Kumagai
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-84171-3

Internet

https://doi.org/10.1038/s41598-021-84171-3

Similar Items